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A hallmark of immunoglobulin A nephropathy (IgAN) is
episodes of gross hematuria coinciding with mucosal
infections that can represent the disease-triggering event.
Here we performed a whole genomic screen of IgAN patients
during gross hematuria to clarify the link between mucosal
antigens and glomerular hematuria. Modulated genes
showed a clear involvement of the intracellular interferon
signaling, antigen-presenting pathway, and the
immunoproteasome. The mRNA and protein level of the
chemokine receptor characterizing cytotoxic effector
lymphocytes, CX3CR1, was upregulated. In vitro antigenic
stimulation of peripheral blood mononuclear cells from IgAN
patients, healthy blood donors, and other nephropathies
with microscopic hematuria showed that only in IgAN
patients was CX3CR1 enhanced in a dose-dependent manner.
A significantly higher amount of glomerular and urinary
fractalkine, the only ligand of CX3CR1, was also found in
IgAN patients with recurrent episodes of gross hematuria
compared with other patients with microscopic or no
hematuria. This suggests a predisposition for cytotoxic cell
extravasation only in patients with recurrent gross
hematuria. Thus, we found a defect in antigen handling in
peripheral blood mononuclear cells of IgAN patients with a
specific increase of CX3CR1. This constitutive upregulation of
glomerular and urinary fractalkine suggests an involvement
of the CX3CR1–fractalkine axis in the exacerbation of gross
hematuria.
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Immunoglobulin A nephropathy (IgAN) is the most common
form of primary glomerulonephritis worldwide among
patients undergoing renal biopsy. Approximately 40% of IgAN
patients, older than 30 years, develop end-stage renal disease
after 20 years from the renal biopsy.1,2 IgAN is characterized by
a dysregulation of the immune system, leading to an abnormal
deglycosylated IgA1 synthesis, selective mesangial IgA1
deposition with ensuing mesangial cell proliferation, and
extracellular matrix expansion, through poorly understood
molecular mechanisms.3,4 Recurrence of IgA deposits in IgAN
patients after transplantation suggests that the abnormality lies
within the immune cells rather than local kidney abnormal-
ities.5,6 Indeed, accumulating evidences suggest that peripheral
blood mononuclear cells (PBMCs) from IgAN patients are
hyperactivated7,8 and show an upregulation of the cellular
machinery involved in antigen processing.9
The most characteristic clinical feature of this disease is gross
hematuria (GH) coinciding with or immediately following
an upper respiratory or gastrointestinal tract infection; thus,
a dysregulation of innate immunity has been extensively
postulated in IgAN.10 A variety of common pathogens and
alimentary components have been used in experimental models
of IgAN, in which oral immunization was able to reproduce
IgAN in mice.11,12 Furthermore, some of these exogenous
antigens were also detected in renal tissue of IgAN patients.13,14
The link between mucosal encountered antigens and the
occurrence of glomerular hematuria has never been clarified.
Increasing evidence suggests an altered cell homing in
IgAN patients.15,16 In particular, altered cell homing from
mucosal to systemic sites has been demonstrated by Batra
et al.16 Chemokines and chemokine receptors have an
important role in the homing and recruitment of specific
immune cell populations in the correct effector sites. Among
the chemokine receptors, chemokine (C-X3-C motif) recep-
tor 1 (CX3CR1) clearly defines peripheral blood cytotoxic
effector lymphocytes commonly armed with intracellular
perforin and granzyme B. These cells include natural killer
cells, gd-T cells, and terminally differentiated CD8þ T cells.17
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Fractalkine (FKN) represents the only ligand for the CX3CR1
receptor. This is a unique chemokine that functions not only
as a chemoattractant but also as a cell adhesion molecule for
CX3CR1þ cells, and thus FKN and CX3CR1 represent a novel
type of leukocyte trafficking regulator.
FKN is expressed on endothelial cells and is activated by
proinflammatory cytokines, such as IFN-g, TNFa, IL-1, and
MCP-1.18 The expression of FKN and the presence of
CX3CR1-expressing cells have been demonstrated in patients
with various types of nephropathies.19–22 In particular, Segerer
et al.22 demonstrated that infiltrating inflammatory leukocytes
in renal diseases express CX3CR1, confirming their role in the
accumulation of intra-renal inflammatory cells. On the other
hand, the treatment with anti-CX3CR1 antibody markedly
blocks the infiltration of leukocytes into the glomeruli,
prevents crescent formation, and improves renal function,
suggesting a role for FKN in the pathogenesis of glomer-
ulonephritis.23 FKN expressed on endothelial cells promotes
adhesion and transmigration of leukocytes that bear the
complementary receptor CX3CR1.24 The transmigration of
CX3CR1þ cells into the tissue has been demonstrated to
damage neighboring endothelial cells and to have a role in
vascular injury.25–27
As GH can represent a triggering event in IgAN, we
decided to study this clinical time point in order to uncover
new mechanisms associated with the onset and development
of IgAN. Genome-wide expression analysis followed by
classical biomolecular approaches uncovered new pathways
involved in the exacerbation of GH, and a central role for the
CX3CR1–FKN axis in this clinical manifestation was revealed.
Furthermore, we confirmed the predisposition of PBMCs
of IgAN patients to respond in an aberrant and enhanced
manner to antigen stimulation.
RESULTS
Differences in gene expression patterns during the acute
phase of the disease
The first step of the study was to perform an exploratory/
hypothesis-generating analysis using microarray technology
in order to identify genes/pathways modulated in the acute
phase of the disease. For this aim, we analyzed the genomic
profile of PBMCs from three IgAN patients at two different
clinical time points; the first sample was analyzed during the
GH episode and the second during the remission phase of
the disease characterized by persistent microscopic hematuria
(MH). During the GH episode, bioinformatic analysis
revealed 150 upregulated (Po0.001) and 96 downregulated
(P¼ 0.043) genes compared with the same subjects in the
MH status (Supplementary Tables S1, S2 online). Ingenuity
pathway analysis (IPA) demonstrated that the identified
genes were primarily involved in interferon signaling, antigen
presentation, and cytotoxic T lymphocyte–mediated apopto-
sis of target cell canonical pathways (Table 1, Supplementary
Figure S1 online). The most representative pathway selected
Table 1 | The most representative canonical pathways dysregulated during the gross hematuria episode
IPA category
Pathway
P-valuea
Pathway corrected
P-valueb Gene symbol Entrez gene name Probe set ID Mean FCc
Interferon signaling 2.95E-6 3.59E-4 IFIT3 Interferon-induced protein with
tetratricopeptide repeats 3
204747_at 8.81
IFITM1 Interferon-induced transmembrane
protein 1
214022_s_at 2.51
MX1 Myxovirusresistance 1, interferon-inducible
protein p78
202086_at 10.06
OAS1 20,50-Oligoadenylate synthetase 205552_s_at 8.57
PSMB8 Proteasome subunit, b type, 8 209040_s_at 1.91
STAT1 Signal transducer and activator of
transcription
200887_s_at 2.31
Antigen presentation
pathway
1.14E-6 2.63E-3 HLA-E Major histocompatibility complex,
class I, E
200905_x_at 1.54
PSMB8 Proteasome subunit, b type, 8 209040_s_at 1.91
PSMB9 Proteasome subunit, b type, 9 204279_at 1.74
TAPBP TAP-binding protein 208829_at 1.47
Cytotoxic T
lymphocyte-
mediated apoptosis
of target cells
6.02E-4 1.21E-2 CD3E CD3e molecule, epsilon g polypeptide 204747_at 8.81
FADD Fas (TNFRSF6)-associated via death domain 214022_s_at 2.51
FAS TNF receptor superfamily (member 6) 202086_at 10.06
FCER1G Fc fragment of IgE, high affinity I, receptor 205552_s_at 8.57
HLA-E Major histocompatibility complex, class I, E 209040_s_at 1.91
TRA@ T-cell receptor a locus 200887_s_at 2.31
CX3CR1 Chemokine (C-X3-C motif) receptor 1 205898_at 1.90
Abbreviations: FC, fold change; Ig, immunoglobulin; IPA, ingenuity pathway analysis; TNF, tumor necrosis factor.
aP-value calculated with Fisher’s exact test by IPA, this P-value determines the significance of the association between the uploded data set and the canonical pathway.
bP-value calculated with the Benjamini–Hochberg method by IPA; this corrected P-value takes into account the multiple canonical pathways tested by IPA.
cThe mean FC was evaluated as the mean of the ratio between the actual probe values in the two experimental conditions, in the three subjects.
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by this analysis showed a clear involvement of the intra-
cellular interferon signaling pathway. Reports conducted
both in vivo and in vitro demonstrated the importance of
our selected genes in the cellular machinery activated by
interferons (Supplementary Table S3 online).28,29 In addition,
the top-ranked network included several genes encoding for
regulators of these pathways (score 48, 54 associated genes,
Po0.0001; Figure 1). Analysis of this network revealed
new important insights related to the pathogenesis of the
GH episode in IgAN. This network showed, for the first
time, an involvement of the immunoproteasome pathway
(e.g., PSMB8, PSMB9, and PSMB10), the central role of
interferon signaling (e.g., STAT1), and the presence of a gene
characterizing cytotoxic effector lymphocytes CX3CR1.
Quantitative real-time PCR for CX3CR1, PSMB9, and FADD
To further establish the validity of gene expression deter-
mined by microarray analysis, we performed quantitative
real-time PCR (RT-PCR) on PBMCs from 12 IgAN patients
from whom blood samples were collected at two clinical time
points. We chose three representative genes that were found
deregulated during the GH: CX3CR1, PSMB9, and FADD.
Normalized gene expression levels for CX3CR1 and PSMB9
were significantly higher during the GH episode compared
with the same subject in the MH phase (*P¼ 0.0001,
**P¼ 0.006, respectively; Figure 2a and b). FADD-normal-
ized gene expression level was significantly lower during the
GH phase (***P¼ 0.01, Figure 2c). Paired t test was applied.
These results were in line with those obtained by the gene
expression array.
CX3CR1 protein levels in IgAN patients during GH
At this point, we focused our attention on the upregulation
of CX3CR1. This receptor clearly defines peripheral
blood cytotoxic effector lymphocytes involved in vascular
injury and glomerulonephritis.17,19–22,25 Flow cytometry and
western blot were used to analyze the expression of CX3CR1
on freshly isolated PBMCs from IgAN patients at two
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Figure 1 | Functional analysis of the top selected genes identified by microarray during the gross hematuria episode. The network
was algorithmically constructed by the ingenuity pathway analysis (IPA) software on the basis of the functional and biological connectivity
of genes. The network is graphically represented as nodes (genes) and edges (the biological relationship between genes). Red and green
shaded nodes represent upregulated and downregulated genes, respectively; others (empty nodes) are those that IPA automatically
includes because they are biologically linked to our genes based on the evidence in the literature. The analysis of this top-ranked network
(score 48, 54 associated genes, Po0.0001) revealed an important role of the immunoproteasome pathway, the central role of STAT1, and
the presence of a gene characterizing cytotoxic effector lymphocytes CX3CR1.
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different time points: during the GH episode and in the
remission phase characterized by persistent MH. The surface
expression of CX3CR1 was found significantly higher in
PBMCs in the GH compared with the same patient
during the MH phase (P¼ 0.001; Figure 3a and b). The
same results were confirmed by western blot analysis.
In accordance with results obtained by flow cytometry,
CX3CR1 protein levels were significantly higher during the
GH compared with the same subject in the MH phase
(P¼ 0.001; Figure 3c and e). Concordant with genome-
wide expression analysis, we also found that STAT1 protein
levels were significantly higher during the GH compared
with the same subject in the MH phase (P¼ 0.002;
Figure 3d and e).
Next, we decided to extend our characterization of
CX3CR1 surface expression in lymphocyte subpopulations
from freshly isolated PBMCs of five IgAN patients at two
clinical time points, in order to evaluate whether the
differences in the receptor expression affect a specific subset.
We found, during the GH episode, a significant increase of
CX3CR1 in cell subsets with well-known cytotoxic effector
functions, such as natural killer cells (CD16þCD56þCD3,
P¼ 0.004), natural killer T cells (CD16þCD56þCD3þ ,
P¼ 0.004), CD3þCD8þ T cells (P¼ 0.025), and g/d-T
cells (CD4CD8CD3þ , P¼ 0.001) (Figure 4a and b). We
noted a significant increase also in CD3þCD4þ T cells
(P¼ 0.006) in the GH even when the percentage expression
of CX3CR1 in this population was lower compared with
CD8þ T cells. Interestingly, we observed that all cytotoxic
cell subsets during the GH episode compared with the
MH tend to expand, except for CD4þ cells, which show
an opposite trend (43 vs. 27%, Figure 4a), but these changes
do not reach statistical significance (data not shown). Paired
t test was applied.
CX3CR1 and STAT 1 expression on PBMCs after in vitro
stimulation
Further, we decided to enroll an independent set of 12 IgAN
patients and 10 healthy blood donors (HBDs) in order to
evaluate whether CX3CR1 expression on PBMCs could be
upregulated specifically in IgAN patients following anti-
genic stimulation. We performed PBMC in vitro stimulation
with increasing concentrations of lipopolysaccharide (LPS;
0.01 mg/ml, 0.1 mg/ml, and 1 mg/ml). LPS exposure resulted in
a dose-dependent upregulation of CX3CR1 and STAT1
proteins in IgAN patients and not in HBDs, reaching a
statistically significant 2.8- and 1.9-fold increase, respectively,
with the dose of 1mg/ml (n¼ 3, *Po0.01, **Po0.05;
Figure 5a). Furthermore, we selected this dosage to evaluate
CX3CR1 and STAT1 protein levels and found, respectively, a
significant 1.8- and 1.6-fold increase in protein expression in
IgAN patients compared with HBDs (Po0.01; Figure 5c
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Figure 2 |Gene expression levels evaluated by real-time (RT)-PCR in peripheral blood mononuclear cells from 12 IgA nephropathy
(IgAN) patients during the gross hematuria (GH) episode and during the remission phase characterized by permanent microscopic
hematuria (MH). (a) CX3CR1- and (b) PSMB9- normalized gene expression levels were significantly higher during the GH phase of the
disease compared with the same subject in the MH phase (*P¼ 0.0001, **P¼ 0.006, respectively). (c) FADD-normalized gene expression level
was significantly lower during the GH phase of the disease compared with the same subject during the MH phase (***P¼ 0.01). P-values
obtained by paired t test.
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and d). The same group was then divided into two clinical
subgroups: IgAN patients who had never manifested GH and
were characterized by permanent asymptomatic MH (pMH,
n¼ 6) and IgAN patients who have had at least three episodes
of GH during the follow-up (recurrent GH, rGH, n¼ 6). We
found no statistically significant differences between the two
clinical subgroups (P¼ 0.8357; Supplementary Figure S2
online). These results suggest that the upregulation of this
receptor is a specific characteristic of cells in IgAN patients
following endotoxin challenge, and that the enhanced
expression is not sufficient to cause GH. In fact, we evaluated
whether the abnormalities in CX3CR1 and STAT1 were also
found in IgAN patients without hematuria and in other
glomerulonephritis characterized by hematuria,30,31 i.e.,
membranous nephropathy (MN) and membranoproliferative
glomerulonephritis (MPGN). CX3CR1 and STAT1 protein
levels in five IgAN patients without hematuria increased 1.9-
and 1.5-fold compared with MN and MPGN patients after
PBMC in vitro stimulation with LPS (1 mg/ml, Supplemen-
tary Figure S3 online). These results confirm that the
deregulation of interferon signaling pathway through STAT1
and the enhanced expression of the receptor during
endotoxin challenge are specific to IgAN patients and do
not occur in other glomerulonephritis characterized by
microhematuria.
Glomerular expression of FKN and its urinary level in IgAN
It is well established that FKN functions as an adhesion
molecule to CX3CR1-positive cells and is capable of
capturing leukocytes under static and physiological flow
conditions.32–34 Thus, we investigated in vivo, by means of
immunohistochemical techniques, whether FKN glomerular
expression was different in rGH compared with pMH
patients. We found that FKN expression was significantly
higher in IgAN patients with a history of rGH compared with
pMH (n¼ 10, Po0.0001) and normal glomeruli (n¼ 10,
P¼ 0.0002; Figure 6a–e), in which the expression was
virtually absent. To strengthen our hypothesis, we measured
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Figure 3 |CX3CR1 and STAT1 protein expression on isolated peripheral blood mononuclear cells (PBMCs) of IgA nephropathy
(IgAN) patients at two different time points: during the gross hematuria (GH) episode and during the remission phase
characterized by permanent microscopic hematuria (MH). (a) Surface marker expression of CX3CR1 as measured by flow cytometry on
PBMCs was significantly higher during the GH (gray line) compared with the same subject during the MH (black line). Histograms are
compared with isotype control MoAB (black solid filled histogram). (b) Surface marker expression of CX3CR1 as measured by flow cytometry
on PBMCs during the GH compared with the same subject in MH (*P¼ 0.001). (c) In accordance with results obtained by flow cytometry,
CX3CR1 protein levels assessed by western blotting showed significantly higher levels during the GH compared with the same subject in
the MH (**P¼ 0.001). (d) STAT1 protein levels assessed by western blotting were significantly higher during the GH compared with the
same subject in the MH (***P¼ 0.002). (e) Representative western blotting experiment for CX3CR1 and STAT1 on two IgAN patients during
the GH and the same subjects in the MH. P-values obtained by paired t test. FITC, fluorescein isothiocyanate.
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the urinary FKN level in IgAN patients with rGH, pMH,
without hematuria, in MN patients with pMH, and in
MPGN patients with pMH. We found a significantly higher
FKN level only in IgAN patients with rGH compared with the
other groups (Po0.05, Figure 6f). Moreover, we assessed the
localization of this expression by immunofluorescent experi-
ments. We found a perfect colocalization of FKN with
glomerular endothelial cells and podocytes as shown by dual
labeling, respectively, with anti-CD31 (Figure 7a–f) and anti-
synaptopodin (Figure 7a–l). Altogether, these results suggest
that the upregulated expression of FKN within the glomer-
ulus of rGH could predispose these patients to the GH
episode.
DISCUSSION
In this study, a whole-genome expression analysis followed by
classical biomolecular approaches revealed new mechanisms
underlying GH episode, which is considered the hallmark
of IgAN.35 The response to an antigenic challenge clearly
emerges from pathway analysis in IgAN patients during
GH. In particular, upregulated genes intervene in the
machinery involved in antigen presentation and in the con-
version of protein antigens into antigenic epitopes. These
processes are controlled by the immunoproteasome P28
(PSMB8, PSMB9, and PSMB10); subsequently, the processed
epitopes are loaded onto the cell surface in a complex
with major histocompatibility complex (MHC) class I
(TAPBP, HLA-E). Once displayed on the cell surface, the
antigen-loaded class I MHC complex is ready for inspection
by the T-cell receptor (TRA@) on circulating cytotoxic
effector lymphocytes (CX3CR1). Surprisingly, a recent
genome-wide association study for IgAN localized the
strongest signal in the genomic area that encodes for TAPBP
and PSMB8, and PSMB9.36 The switch from proteasome
to immunoproteasome has already been described in IgAN
patients at basal levels;9 however, our data support the
hypothesis that these upregulated genes reflect a response to
an infectious challenge during the active phase of the disease.
IFN-g is a key pleiotropic regulatory cytokine in this
context,37 explaining the interferon signature in our data
set and the activation of STAT1.
We demonstrate, for the first time, the upregulation of
CX3CR1 at both mRNA and protein levels in PBMCs of
IgAN patients and, in particular, in cytotoxic effector
lymphocytes during the GH episode. The expression of this
receptor aroused our interest, as it characterizes a group of
fully differentiated effector lymphocytes, regardless of their
lineage or mode of action. These cytotoxic lymphocytes are
essential for host defense against intracellular pathogens
and altered self-cells; however, their excessive activities
lead to organ-specific autoimmune diseases.38–40 A limita-
tion of this study, however, is the absence of a control
group comprising IgAN patients with acute infections and
absent GH, as these patients do not seek nephrologists’
medical advice.
Our findings, based on the in vitro antigenic stimulation
of PBMCs, document that these cells from IgAN patients do
effectively upregulate specifically this receptor in an enhanced
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and dose-dependent manner. On the other hand, the kinetics
related to the failed upregulation of CX3CR1 following
LPS stimulation in HBDs is consistent with previously
published reports.41,42 It has been demonstrated that
interferon-g treatment abrogated the CX3CR1 down-mod-
ulation through a phosphatidylinositol 3 kinase–dependent
pathway;41 the constitutive hyperactivation of this pathway
seen in PBMCs of IgAN patients7 and the STAT1 activation
could explain the aberrant response of these patients
following LPS stimulation.
IgAN is characterized by various phenotypical manifesta-
tions. Reviews state that 20% of patients undergo repeatedly
glomerular GH, and 72% bare asymptomatic permanent
MH with or without proteinuria; the others never bare
hematuria.43 We found that all groups of IgAN patients
reacted in the same enhanced manner following LPS
stimulation even compared with another type of glomer-
ulonephritis characterized by hematuria. These results
demonstrate that the upregulation of this receptor is specific
to the IgAN regardless of their potential phenotypical
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Figure 5 |CX3CR1 and STAT1 protein expression levels in peripheral blood mononuclear cells (PBMCs) of 12 IgA nephropathy
(IgAN) patients and 10 healthy blood donors (HBD) in response to antigenic stimuli. (a, b) CX3CR1 and STAT1 expression increased in
a dose-dependent manner only in IgAN patients and not in HBDs, reaching a statistically significant fold increase with the dose of 1 mg/ml
(n¼ 3). (c, d) CX3CR1 and STAT1 protein levels, assessed by western blotting, showed, respectively, a 1.8- and 1.6-fold increase in IgAN
patients compared with HBDs after lipopolysaccharide (LPS) stimulation (1 mg/ml). (e) Representative western blotting experiment for
CX3CR1 and STAT1 of an IgAN patient and HBD. The histograms represent the mean±s.e.m. of CX3CR1 protein levels (*Po0.01, **Po0.05).
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manifestation; therefore, the expression of this receptor could
be necessary, but not sufficient, for exacerbating GH.
Thus, our attention was directed toward FKN expression,
as CX3CR1-expressing cells bind rapidly and with high
affinity to immobilized FKN or FKN-expressing cells in both
static and physiological flow conditions.32–34 On the other
hand, excessive activation of cytotoxic lymphocytes together
with FKN expression on endothelial cells has been demon-
strated to cause incidental vascular damage during transmi-
gration.25–27 We demonstrated that the upregulation of FKN
in podocytes and endothelial cells and the enhanced urinary
level of this chemokine in IgAN patients with recurrent GH
during the latent phase could act as a vascular gateway for
CX3CR1þ cells toward the urinary pole during the acute
phase. This transmigration could cause endothelial injury
and thus GH (Figure 8). Clinical practice does not consent
biopsies during the GH episode, and thus we were not able to
obtain data regarding FKN glomerular expression during the
acute phase of the disease, but a break in continuity of a
glomerular capillary has been documented and could explain
the presence of dysmorphic erythrocytes and blood cells in
the urine.44 The FKN/CX3CR1 axis has been extensively
demonstrated in various types of glomerulonephritis,19–22
and the participation of this axis may be a common signaling
pathway involved in other diseases characterized by glomer-
ular hematuria.45
In conclusion, we found hyperactivation of genes that
intervene in the cellular machinery involved in antigen
presentation and a defect in antigen handling in LPS-
stimulated PBMCs from IgAN patients. Furthermore, a
possible link between mucosal encountered antigens and the
occurrence of glomerular hematuria has been identified
involving CX3CR1-positive leukocytes; these cells are direc-
ted toward the increased endothelial FKN expression and
their extravasation could explain the glomerular capillary
damage during GH.
MATERIALS AND METHODS
Sample collection
A total of 79 biopsy-proven IgAN patients, 5 MN and 3 MPGN
patients with MH, and 10 HBDs were included in the whole study
after providing their informed consent. The main demographic and
clinical features of patients and controls, included in the study, are
summarized in Table 2. There were no statistically significant
differences between the groups for all parameters considered. All
IgAN patients were characterized by a normal renal function as
defined by an estimated glomerular filtration rate 490ml/min per
1.73m2 body surface area (evaluated by Cockcroft–Gault formula,
I K-DOQI stage) with mild/moderate histological lesions (G1–G2
according to our recent report)46 and mild protenuria. In addition,
subjects suffering from diabetes, chronic lung disease, cardiovascular
diseases, neoplasm, or inflammatory diseases, and IgAN patients
receiving corticosteroids and immunosuppressive agents were
excluded from the study. All patients had a follow-up of at least
10 years. Peripheral blood was collected from 12 IgAN patients at
two different clinical time points; the first sample was drawn within
48 h after patients acknowledged red-stained urine (GH) and the
second during the remission phase of the disease in which the
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Figure 6 |Glomerular immunolocalization and urinary level
of fractalkine (FKN). (a) Strong deposition of FKN was found in
the glomerulus of a patient with a history of recurrent gross
hematuria (rGH) episodes after upper respiratory tract infections.
(b) Magnified image of a showing diffused staining that
corresponds to the secreted form of FKN (b, red arrow) and a
more linear staining that corresponds to the membrane-bound
form (b, black arrow,  100 objective magnification). (c) Weak
glomerular FKN expression was found in IgA nephropathy (IgAN)
patients who had permanent microscopic hematuria (pMH) and
(d) in normal biopsy specimens. (e) FKN-specific staining in the
glomerular area was higher in the rGH group compared with pMH
(Po0.0001) and controls (P¼ 0.002); no statistical difference was
found when we compared pMH and controls. Quantification of
the extent of immunoperoxidase staining was carried out as
described in the Materials and Methods and Supplementary
Methods online section. (f ) Urinary level of fractalkine was higher
in IgAN patients with rGH patients compared with pMH patients
(P¼ 0.005), IgAN patients without microscopic hematuria
(w/o H, P¼ 0.04), membranous nephropathy patients with
microscopic hematuria (MN, P¼ 0.001), and membranoproliferative
glomerulonephritis patients with microscopic hematuria
(MPGN, P¼ 0.04). Values are expressed as mean±s.e.m.
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patient was free from respiratory or gastric infections and hematuria
only detectable by urinalysis or light microscopy (MH). The main
clinical parameters of this study population are summarized in
Supplementary Table S4 online. For microarray analysis, we
randomly selected three patients and compared their gene expres-
sion profile at two different time points. RT-PCR validation of
microarray data was performed on 12 patients, whereas flow
cytometry and western blot analysis were performed in 10 out of the
12 IgAN patients; the samples were collected at two clinical time
points. PBMC in vitro stimulation assays were performed on an
independent set of 12 IgAN patients, 5 IgAN patients without
hematuria, 5 MN and 3 MPGN patients, and 10 HBDs; these
samples were all collected when free from systemic inflammation.
Twenty kidney specimens were obtained by renal biopsy in the
absence of clinical activity (i.e., GH) from 10 IgAN patients who
have had at least three episodes of GH during the follow-up (rGH)
and from 10 IgAN patients with pMH, defined as patients who
during the follow-up document permanent asymptomatic MH
without ever-reporting GH. Furthermore, five histologically exam-
ined healthy portions of kidney, removed for renal cell carcinoma,
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Figure 7 |Glomerular expression of fractalkine (FKN) in IgA nephropathy (IgAN) patients characterized by recurrent gross
hematuria episodes. Immunofluorescent labeling of FKN in biopsy specimens, with histological diagnosis of IgA nephropathy. We found a
perfect colocalization of FKN within glomerular endothelial cells, as shown by (a–f) dual labeling with anti-CD31 and within podocytes as
shown by (g–l) dual labeling with anti-synaptopodin.
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were used as controls. Urinary samples were obtained from an
independent set of 35 IgAN patients, 5 MN, and 3 MPGN patients.
These disease controls were selected with the same demographic and
clinical features of IgAN patients. The study was carried out
according to the Declaration of Helsinki Principles and was
approved by our institutional ethics review board.
PBMC isolation and RNA extraction
PBMCs were isolated by density separation over a Ficoll–Hypaque
and used for total RNA extraction by means of the RNeasy Mini kit
(Qiagen, Basel, Switzerland). RNA concentration and quality were
assessed with NanoDrop Spectrophotometer (Nanodrop Technolo-
gies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA), respectively.
Gene expression profiling
We randomly selected three patients for microarray expression
profiling. RNAwas isolated from PBMCs at two clinical time points,
and processed and hybridized to the GeneChip Human Genome
U133A oligonucleotide microarray (Affymetrix, Santa Clara, CA).
The data discussed in this publication have been deposited in NCBIs
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and
are accessible through GEO Series accession number GSE27676.
Quantitative (RT-PCR) analysis
A measure of 1 mg of total RNA was reverse transcribed and RT-PCR
amplification reactions were performed for CX3CR1, PSMB9, and
FADD using the QuantiTect Primer Assay and the QuantiFast SYBR
Green PCR mix (Qiagen). The b-actin gene amplification was used
as a reference standard to normalize the target signal.
Flow cytometric analysis
Freshly isolated PBMCs were washed and resuspended in FACS
buffer and incubated with fluorochrome-conjugated monoclonal
antibodies (mAbs; FITC-CX3CR1, PE-CD4, ECD-CD3, PE-Cy-5-
CD8, PE-16/56). Cells were analyzed on a ‘EPICS XL’ Flow
Cytometer (Beckman Coulter, Brea, CA) and analyzed using the
WinMDI Version 2.9 software. The area of positivity was
determined using an isotype-matched mAb; a total of 104 events
for each sample were acquired.
Western blot analysis for CX3CR1 and STAT1
PBMCs were lysed in RIPA buffer and total protein concentration
was determined with the standard Bradford colorimetric assay. A
measure of 80 mg of proteins from each lysate was subjected to
SDS–polyacrylamide gel electrophoresis and then electrotransferred
onto polyvinylidene difluoride membrane (HybondTM, Amersham,
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Figure 8 |Potential pathogenic mechanism in IgA nephropathy (IgAN) patients characterized by recurrent episodes of gross
hematuria (rGH). Antigenic stimuli enhance CX3CR1 expression on circulating blood cytotoxic effector cells including natural killer (NK)
cells, CD8þ T cells, and gd-T cells, which contain cytoplasmic granules of perforin and granzyme. IgAN patients who have permanent
microscopic hematuria (pMH) are characterized by low glomerular fractalkine (FKN) expression. On the other hand, IgAN patients
characterized by rGH during the follow-up have an enhanced FKN expression by both podocytes and endothelial cells (ECs) and an
enhanced urinary level of this chemokine. FKN captures CX3CR1þ cells under both static and flow conditions. The CX3CR1–FKN interaction
promotes transendothelial migration of cytotoxic effector cells, leading to a break in continuity of the glomerular capillary wall. This
mechanism may explain the massive presence of red blood cells in the urine during the GH. GBM, glomerular basement membrane.
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UK). Membranes were probed with primary antibodies for CX3CR1
and STAT1, incubated with horseradish peroxidase–coniugated
secondary antibody, and detected with ECL method. The same
membranes were stripped and proteins were rehybridized with anti-
b-actin antibody. Images were quantified by the Image J 1.34
Software (http://rsb.info.nih.gov/ij/). The intensity of bands was
normalized to the actin signal.
Cell culture experiments
PBMCs were cultured in six-well plates in complete culture
medium at 37 1C in 5% CO2. Increasing concentrations of LPS
(0.01mg/ml, 0.1 mg/ml, 1 mg/ml, Sigma, Milan, Italy) were added to
the appropriate wells and cultured for 24 h; the cells were then spun
down and lysed.
Immunohistochemistry
Immunohistochemical evaluation of FKN protein was performed
on renal biopsy specimens from IgAN patients. The cortical
fragment from the unaffected pole of kidneys removed for renal
cell carcinoma was used as control tissue. Paraffin-embedded
sections, after specific epitope unmasking and blocking,
were incubated with a rabbit polyclonal anti-human FKN
antibody (Abcam, Cambridge, UK). The binding of the secondary
biotinylated antibody was detected by the Dako Real EnVision,
Peroxidase/DAB kit (Dako, Glostrup, Denmark). Two independent
observers blinded to the origin of the slides performed the
immunohistochemical quantification.
Immunofluorescence and confocal laser scanning microscopy
Paraffin-embedded renal biopsy specimens of IgAN patients were
double-stained for FKN and CD31 or synaptopodin. The slides were
incubated with the blocking solution, primary antibodies, and
secondary antibodies. The stained cells were viewed under the Leica
TCS SP2 confocal laser scanning microscope.
Enzyme-linked immunosorbent assay assay for urinary FKN
All urinary samples were centrifuged at 600 g for 5min and stored at
80 1C. The soluble form of FKN was detected in urinary samples
using a standardized Quantikine enzyme-linked immunosorbent
assay (R&D Systems, Abingdon, UK) according to the manufac-
turer’s protocol. FKN level was expressed per millimole of urinary
creatinine to correct for differences in urinary concentration.
Statistical analysis and bioinformatics
For microarray analysis, the gene expression profile of each subject
enrolled in the study was reduced from 22,283 to 3404 probe sets
present and was common to all the three subjects (see Supplemen-
tary Methods online for details). Because of the small number of
subjects analyzed and, more importantly, because of the limited
number of genes truly associated with the phenotype, the classical
methods47 may not reliably identify any statistically significant
differentially expressed gene. Therefore, for selecting promising
genes consistently deregulated in all the subjects analyzed, we
applied an approach based on the level of up/downregulation.48,49
We obtained a list of 150 upregulated probes (P-valueo0.001) and a
list of 96 downregulated ones (P-value¼ 0.043). The statistical
significance of the obtained lists was assessed with nonparametric
permutation tests. To assess biological relationships among
differently regulated genes, we used the Ingenuity Pathway Analysis
software (IPA, Ingenuity System, Redwood City, CA; http://
www.ingenuity.com). We performed a network and a canonical
pathway analysis. IPA generates networks based on the connectivity
of the genes and computes a score for each network. These scores
indicate the likelihood of focus genes to belong to a network vs.
those obtained by chance. Canonical pathway analysis identifies the
pathways, from the IPA library of canonical pathways, that were
most significant to the input data set. Fisher’s exact test and
Benjamini–Hochberg option was used to calculate the significance of
the canonical pathway.
For the remaining experimental analysis, all values were
expressed as the mean±s.e.m. of data obtained from at least three
independent experiments. Two-tailed paired and unpaired Student’s
t test was used to assess differences in biological features. Po0.05
was considered statistically significant.
ADDITIONAL SUPPLEMENTARY METHODS
An extended version of the Materials and Methods section is
provided in the Supplementary Material online.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We are grateful to the patients for their cooperation in this study. We
are grateful to M. Carella for microarray hybridization. We also thank
Table 2 |Demographic and clinical features of primary glomerulonephritis patients and healthy subjects included in the studya
IgAN-PBMCs IgAN-BIOPSY IgAN-URINE MN MPGN HBS
Number 24 20 35 5 3 10
Male/female 16/8 14/6 23/12 4/1 1/2 8/2
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